Why Did DAWN Skyrocket Over 65% Pre-Market Today?

• The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments.
• This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030.
• In February, Day One reported strong momentum for its lead therapy, OJEMDA.

Day One Biopharmaceuticals, Inc. (DAWN) announced on Friday that it has entered into an acquisition agreement with Servier, an independent pharmaceutical company managed by a foundation.

The deal, valued at roughly $2.5 billion, will see Servier purchase Day One shares for $21.50 each in cash, marking a 64% premium over DAWN’s closing price on Thursday.

Expansion In Oncology

The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments and broaden its cancer pipeline for both adults and children facing high unmet medical needs.

Following the announcement, Day One Biopharmaceuticals stock surged over 65% on Friday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.

Pipeline Growth And 2030 Ambition

This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030. The addition of Day One’s programs, ranging from early-stage research to phase 3 trials, enhances Servier’s capacity to deliver solutions for cancers with critical unmet needs.

“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma.”

-Jeremy Bender, CEO, Day One

In February, Day One reported strong momentum for its lead therapy, OJEMDA, highlighting prescription volumes for OJEMDA reached 1,394 in the fourth quarter of 2025, with total prescriptions for the year at 4,635, marking a 181% year-on-year (YOY) growth. 

The company said updated three-year results from the Phase 2 FIREFLY-1 trial demonstrated durable responses and long-term safety of OJEMDA in relapsed or refractory pediatric low-grade glioma (pLGG). Enrollment for the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on schedule, with full enrollment expected in the first half of 2026.

DAWN stock traded over 132% in the last 12 months. 

Also See: ASPI Stock In Spotlight As Company Strengthens US Nuclear Fuel Supply Chain With New Deal

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on